Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
复制标题
DOI：
10.1186/s12885-018-4819-2
复制
发表时间：
2018-10-03
期刊：
影响因子：
3.8
通讯作者：
Yokota S
中科院分区：
文献类型：
--
作者：
Tachihara M;Negoro S;Inoue T;Tamiya M;Akazawa Y;Uenami T;Urata Y;Hattori Y;Hata A;Katakami N;Yokota S
免疫检查点抑制剂（ICI）已成为非小细胞肺癌（NSCLC）的有前途的治疗药物。然而，持续时间的ICI应该继续仍然是一个临床问题。我们在NSCLC患者中检查了由于不良事件（AE）而停用抗体后抗PD-1/PD-L1抑制剂的疗效。这是一项多中心回顾性研究，分析了截至2016年8月接受PD-1/PD-L1抑制剂治疗的NSCLC患者。NSCLC患者为18例男性和1例女性，中位年龄为67岁（范围：49-80岁）。19例患者中有18例接受了nivolumab治疗，1例接受了atezolizumab治疗。大约一半的AE为间质性肺炎。14例（73.7%）患者接受了类固醇治疗。中位治疗周期数为7（范围：1-70），中位治疗持续时间为2.8个月（范围：1天-32.9个月）。治疗期间确认的总体缓解率为21.1%。从PD-1/PD-L1治疗开始和停止，中位无进展生存期（PFS）分别为10.2个月（95%置信区间[CI] = 3.2-17.1个月）和5.6个月（95% CI = 0-12.2个月）。根据给药期间确认的缓解，部分缓解（PR）患者停药后的中位PFS未达到，疾病稳定（SD）患者停药后的中位PFS为4.9个月（95% CI，3.7-6.0）（P = 0.02）。PR患者的PFS与SD患者完全不同。AE发生前PR的病例倾向于在PD-1/PD-L1抑制剂停药后显示持久缓解。本文的在线版本（10.1186/s12885-018-4819-2）包含补充材料，可供授权用户使用。
Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. We examined the efficacy of anti-PD-1/PD-L1 inhibitors after the discontinuation of antibodies due to adverse events (AEs) in patients with NSCLC. This was a multicenter retrospective study that analyzed NSCLC patients who were treated with PD-1/PD-L1 inhibitors by August 2016. The patients with NSCLC were 18 males and 1 female at a median 67 years of age (range: 49–80 years). Eighteen of 19 patients were treated with nivolumab, one was with atezolizumab. Approximately half of AEs were interstitial pneumonia. Fourteen patients (73.7%) were treated with steroid therapy. The median number of treatment cycles was 7 (range, 1–70), and the median duration of treatment was 2.8 months (range, 1 day-32.9 months). The overall response rate with confirmation during treatment was 21.1%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI] = 3.2–17.1 months) and 5.6 months (95% CI = 0–12.2 months) from the initiation and the discontinuation of PD-1/PD-L1 treatment, respectively. The median PFS after discontinuation according to the confirmed response during administration was not reached for partial response (PR) and 4.9 months (95% CI, 3.7–6.0) for stable disease (SD) patients (P = 0.02). The PFS of the PR patients was completely different from that of the SD patients. The cases with PR prior to the onset of AE tended to show a durable response after the discontinuation of PD-1/PD-L1 inhibitors. The online version of this article (10.1186/s12885-018-4819-2) contains supplementary material, which is available to authorized users.
登录
查看更多内容
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
DOI：
10.1073/pnas.192461099
发表时间：
2002-09-17
影响因子：
11.1
作者：
Iwai, Y;Ishida, M;Minato, N
通讯作者：
Minato, N
影响因子：
50.5
作者：
Champiat, S.;Lambotte, O.;Marabelle, A.
通讯作者：
Marabelle, A.
DOI：
10.1056/nejmoa1504627
发表时间：
2015-07-09
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer J;Reckamp KL;Baas P;Crinò L;Eberhardt WE;Poddubskaya E;Antonia S;Pluzanski A;Vokes EE;Holgado E;Waterhouse D;Ready N;Gainor J;Arén Frontera O;Havel L;Steins M;Garassino MC;Aerts JG;Domine M;Paz-Ares L;Reck M;Baudelet C;Harbison CT;Lestini B;Spigel DR
通讯作者：
Spigel DR
影响因子：
158.5
作者：
Garon, Edward B.;Rizvi, Naiyer A.;Gandhi, Leena
通讯作者：
Gandhi, Leena